Literature DB >> 20169327

[Chances and limitations of chemotherapy in elderly patients].

U Wedding1.   

Abstract

The chronological age of a patient should not be a barrier to apply chemotherapy. Elderly patients can benefit from chemotherapy. Chronological age should not be a reason for diagnostic or therapeutic nihilism, as the age of a patient poorly characterizes their health situation. Data with high level of evidence on treatment of elderly patients with cancer are limited. A comprehensive geriatric assessment (CGA) describes the individual deficits and resources of a patient much better. Limitations in CGA are risk factors for increased toxicity and decreased treatment benefit. The currently available data demonstrate under- and over-treatment in elderly patients with cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20169327     DOI: 10.1007/s00108-010-2601-x

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  31 in total

1.  First--select the target: better choice of adjuvant treatments for breast cancer patients.

Authors:  A Goldhirsch; A S Coates; R D Gelber; J H Glick; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2006-10-27       Impact factor: 32.976

2.  Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904).

Authors:  Shinzoh Kudoh; Koji Takeda; Kazuhiko Nakagawa; Minoru Takada; Nobuyuki Katakami; Kaoru Matsui; Tetsu Shinkai; Toshiyuki Sawa; Isao Goto; Hiroshi Semba; Takashi Seto; Masahiko Ando; Taroh Satoh; Naruo Yoshimura; Shunichi Negoro; Masahiro Fukuoka
Journal:  J Clin Oncol       Date:  2006-08-01       Impact factor: 44.544

Review 3.  Tolerance to chemotherapy in elderly patients with cancer.

Authors:  Ulrich Wedding; Friedemann Honecker; Carsten Bokemeyer; Ludger Pientka; Klaus Höffken
Journal:  Cancer Control       Date:  2007-01       Impact factor: 3.302

4.  A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.

Authors:  D J Sargent; R M Goldberg; S D Jacobson; J S Macdonald; R Labianca; D G Haller; L E Shepherd; J F Seitz; G Francini
Journal:  N Engl J Med       Date:  2001-10-11       Impact factor: 91.245

5.  Use and outcomes of adjuvant chemotherapy in older women with breast cancer.

Authors:  Sharon H Giordano; Zhigang Duan; Yong-Fang Kuo; Gabriel N Hortobagyi; James S Goodwin
Journal:  J Clin Oncol       Date:  2006-06-20       Impact factor: 44.544

6.  Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).

Authors:  Pauline Wimberger; Nils Lehmann; Rainer Kimmig; Alexander Burges; Werner Meier; Berit Hoppenau; Andreas du Bois
Journal:  Gynecol Oncol       Date:  2005-09-29       Impact factor: 5.482

7.  Who should not receive adjuvant chemotherapy? International databases.

Authors:  J Bergh; M Holmquist
Journal:  J Natl Cancer Inst Monogr       Date:  2001

8.  Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer.

Authors:  Vijaya Sundararajan; Nandita Mitra; Judith S Jacobson; Victor R Grann; Daniel F Heitjan; Alfred I Neugut
Journal:  Ann Intern Med       Date:  2002-03-05       Impact factor: 25.391

9.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Authors:  Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

10.  Barriers to clinical trial participation by older women with breast cancer.

Authors:  M Margaret Kemeny; Bercedis L Peterson; Alice B Kornblith; Hyman B Muss; Judith Wheeler; Ellis Levine; Nancy Bartlett; Gini Fleming; Harvey J Cohen
Journal:  J Clin Oncol       Date:  2003-06-15       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.